135304-07-3

135304-07-3 structure

Name: N-Acetyl-L-farnesylcysteine
Chemical Name: Ac-Cys(farnesyl)-OH
CAS Number: 135304-07-3
Molecular Formula: C₂₀H₃₃NO₃S
Molecular Weight: 367.546
Catalog: Biochemical Amino acids and their derivatives Cysteine derivative
Create Date: 2018-12-21 18:28:51
Modify Date: 2024-01-02 10:51:23
Arazine (N-Acetyl-S-farnesyl-L-cysteine) is a cell-permeable modulator of G protein and G-protein coupled receptor signaling. Arazine can be a a substrate for isoprenylcysteine methyltransferase by competing with prenylated G protein or its receptors site[1].

Name	Ac-Cys(farnesyl)-OH
Synonyms	L-Cysteine, N-acetyl-S-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]- N-Acetyl-S-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]-L-cysteine N-Acetylfarnesylcysteine N-acetyl-S-farnesyl-L-Cysteine N-acetyl-S-farnesylcysteine Arazine N-Acetyl-S-trans,trans-farnesyl-L-cysteine N-AFC afc

Description	Arazine (N-Acetyl-S-farnesyl-L-cysteine) is a cell-permeable modulator of G protein and G-protein coupled receptor signaling. Arazine can be a a substrate for isoprenylcysteine methyltransferase by competing with prenylated G protein or its receptors site[1].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	Arazine (2 hours) inhibits ATPγS induced CXCL1, CXCL8 and CCL2 production as a dose-dependent manner in HMEC-1 cell[1]. Arazine (10–100 μM;8 hours) significantly affects the HMEC-1 cell viability as measured by trypan blue exclusion in HMEC-1 cell[1].
In Vivo	Arazine (AFC) (2,000 μg/20 μl; applied on ear) produces a dose-dependent inhibition of the TPA-induced edema, with the maximal reduction of edema approaching 73%, with a 50% effective dose (ED50) of 55±12 μg/20 μl[1]. Animal Model: TPA-induced ear acute inflammation in mouse[1] Dosage: 2000 μg/20 μl Administration: 2000 μg/20 μl; Applied on ear Result: Inhibited ear edema, as measured by ear weight.
References	[1]. Gordon JS, et al. Topical N-acetyl-S-farnesyl-L-cysteine inhibits mouse skin inflammation, and unlike dexamethasone, its effects are restricted to the application site.J Invest Dermatol. 2008 Mar;128(3):643-54. Epub 2007 Sep 20. [2]. Adhami K, et al. N-acetyl-S-farnesyl-l-cysteine suppresses chemokine production by human dermal microvascular endothelial cells.Exp Dermatol. 2012 Sep;21(9):700-5.